2019年4月10日，美国创新药公司CullgenInc.宣布，获得来自著名风险投资公司红杉资本中国及弘晖资本1600万美元的A轮融资。Cullgen是一家致力于小分子蛋白质降解药物研发的生物技术公司。本轮融资将支持Cullgen在肿瘤学和其他疾病领域中靶向蛋白质降解的新药研发，以及研究可用作靶向蛋白质降解复合物的新型E3配体，并推动蛋白质讲解药物的产品管线进展。
“我们很高兴得到红杉资本中国和弘晖资本的支持”，Cullgen董事长兼总裁罗楹博士说，“自2018年初成立以来，我们已经取得了显著的进步。我们的目标蛋白质降解平台具有很高的领先水平，并且我们的多种临床前项目正在向临床研究迅速推进中。除了这些核心科学进步之外，在过去的一年中，公司还组建了一个杰出的科学顾问委员会，建立了一个优秀的高级管理团队和一个先进的实验室设施，其中包括40多名才华横溢的科学家。我们很高兴红杉资本中国和弘晖资本成为Cullgen开发用于治疗重大疾病的新型白象蛋白质降解剂的使命的一部分。”
Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein DegradersSeries A financing led by two leading global venture capital firms – Sequoia Capital China and Highlight Capital
SAN DIEGO----Cullgen Inc. , a biotechnology company dedicated to the development of targeted protein degraders for the treatment of diseases lacking effective therapeutic approaches, today announced it has received a $16 million Series A financing from two prominent international venture capital firms, Sequoia Capital China and Highlight Capital . The financing will support the development of Cullgen’s internal pipeline of targeted protein degraders in oncology and other diseases, as well as the company’s efforts to discover novel E3 ligands that may be used as part of a targeted protein degrader complex. Sequoia will also assign a board member to join the Cullgen board.
“We are delighted to have the support of Sequoia and HC”, said Dr. Ying Luo, Chairman and President of Cullgen “Since our founding in early 2018 we have made significant advancement of our targeted protein degradation platform which has directly led to the identification of several pre-clinical assets that we are rapidly advancing towards the clinic. In addition to these core scientific advancements, over the past year the company has assembled a distinguished board of scientific advisors, put in place an outstanding senior management team, and established a state-of-the-art laboratory facility that is run by more than 40 highly talented employees. We are grateful that Sequoia and HC will be part of Cullgen’s mission to develop novel targeted protein degraders for the treatment of debilitating diseases.”
AboutCullgenInc.:Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology. The company"s research programs focus on novel treatment for cancer, inflammatory, and autoimmune diseases. For more information, visitwww.cullgen.com.
AboutuSMITE™:uSMITE™ is Cullgen’s proprietary targeted protein degradation platform that is used to identify novel degraders that attach to a disease-causing protein and then signal the body’s ubiquitin proteasome system to eliminate the protein.
AboutSequoiaChina:Sequoiateamhelpsdaringfoundersbuildlegendarycompanies.InpartneringwithSequoia,companiesbenefitfromourunmatchedcommunityandthelessonswe’velearnedover47years.As“TheEntrepreneursBehindTheEntrepreneurs”,Sequoiafocusesonfoursectors:TMT,healthcare,consumer/service,andindustrialtechnologywithaprivilegeofworkingwithmorethan500companiesinChinaoverthepast14years.
AboutHighlightCapital:HC currently manages both RMB & USD funds with a total AUM of nearly US$1.5 billion. Since the inception in 2014, the firm has invested in over 40 deals. HC is dedicated to supporting healthcare companies to generate robust and sustained growth prospect, and partnering with entrepreneurs of dedication and the highest standard.
Contacts
Cullgen Inc.Thomas Eastling, +81-3-6214-3600inquiries@cullgen.com
